Evidence map›Paper›PMID 37462763›Full record

ArticleCancer immunology, immunotherapy : CII2023

Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy.

Siqi Xiong, Wenqiang Zhu, Liqing Wu, Tianmin Zhou, Wu Wang, Ouyang Zhang, Xiaoliang Xiong, Zhuoqi Liu, Daya Luo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Circadian clock and cancer.Military Medical Research · 2026
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Siqi Xiong *School of Medicine, Queen Mary Institute, Nanchang University, Nanchang, 330006, China.
Wenqiang Zhu *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, 330006, China.
Liqing WuDepartment of Pathology, First Hospital of Nanchang City, Nanchang, 330008, Jiangxi, China.
Tianmin ZhouPathology Department, Infectious Diseases Hospital of Nanchang University, Nanchang, 330006, China.
Wu WangPathology Department, Infectious Diseases Hospital of Nanchang University, Nanchang, 330006, China.
Ouyang ZhangThe First Clinical Department, Nanchang University, Nanchang, 330006, China.
Xiaoliang XiongDepartment of Pathology, School of Basic Medical Sciences, Nanchang University, Nanchang, 330006, China.
Zhuoqi LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, 330006, China. liuzhuoqi@ncu.edu.cn.
Daya LuoDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, 330006, China. luodaya@ncu.edu.cn.
Nanchang University · CN

Funding

National Natural Science Foundation of China 81560464
6 · The paper itself

Abstract

backgroundWhile epidemiological studies have established a firm link between circadian disruption and tumorigenesis, the role and mechanism are not fully understood, complicating the design of therapeutic targets related to circadian rhythms (CR). Here, we aimed to explore the intertumoral heterogeneity of CR and elucidate its impact on the tumor microenvironment (TME), drug sensitivity, and immunotherapy.

methodsBased on unsupervised clustering of 28 CR genes, two distinct CR subtypes (cluster-A and cluster-B) were identified in the TCGA cohort. We further constructed a circadian rhythm signature (CRS) based on the CR genes primarily responsible for clustering to quantify CR activity and to distinguish CR subtypes of individual patients from external datasets. CR subtypes were evaluated by TME characteristics, functional annotation, clinical features, and therapeutic response.

resultsThe cluster-B (low-CRS) group was characterized by highly enriched immune-related pathways, high immune cell infiltration, and high anti-tumor immunity, while the cluster-A (high-CRS) group was associated with immunosuppression, synaptic transmission pathways, EMT activation, poor prognosis, and drug resistance. Immunohistochemistry (IHC) results demonstrated that high CD8

conclusionIn a nutshell, the cross talk in CR could reflect the TME immunoreactivity in breast cancer. Besides providing the first comprehensive pathway-level analysis of CR in breast cancer, this work highlights the potential clinical utility of CR for immunotherapy.

Indexed as

Breast NeoplasmsCarcinogenesisCD8-Positive T-LymphocytesFemaleHumansImmunosuppression TherapyImmunotherapyPrognosisTumor MicroenvironmentBreast cancerCircadian rhythmImmune checkpointImmunotherapyTumor microenvironment

Identifiers

PMID37462763
PMCPMC10992018
OpenAlexW4384626342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.